PPFIBP2 and cholangiocarcinoma: We collected six CCA cell lines, including three iCCA (HuCCT1, CCLP1, and TKKK) and three eCCA (QBC‐939, TFK‐1, and EGI‐1), and treated them with three VEGF/VEGFR inhibitors (Brivanib, BIBF‐1120, and Cediranib), in vivo.